Targeted Radionuclide Therapy: Practical Applications and Future Prospects
- PMID: 27226737
- PMCID: PMC4874742
- DOI: 10.4137/BIC.S31804
Targeted Radionuclide Therapy: Practical Applications and Future Prospects
Abstract
In recent years, there has been a proliferation in the development of targeted radionuclide cancer therapy. It is now possible to use baseline clinical and imaging assessments to determine the most effective therapy and to tailor this therapy during the course of treatment based on radiation dosimetry and tumor response. Although this personalized approach to medicine has the advantage of maximizing therapeutic effect while limiting toxicity, it can be challenging to implement and expensive. Further, in order to use targeted radionuclide therapy effectively, there is a need for multidisciplinary awareness, education, and collaboration across the scientific, industrial, and medical communities. Even more important, there is a growing understanding that combining radiopharmaceuticals with conventional treatment such as chemotherapy and external beam radiotherapy may limit patient morbidity while improving survival. Developments in radiopharmaceuticals as biomarkers capable of predicting therapeutic response and targeting disease are playing a central role in medical research. Adoption of a practical approach to manufacturing and delivering radiopharmaceuticals, assessing patient eligibility, optimizing post-therapy follow-up, and addressing reimbursement issues will be essential for their success.
Keywords: oncology; radionuclide therapy; targeted.
Similar articles
-
MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.J Nucl Med. 2008 Nov;49(11):1884-99. doi: 10.2967/jnumed.108.053173. Epub 2008 Oct 16. J Nucl Med. 2008. PMID: 18927342
-
Targeted alpha therapy: part I.Curr Radiopharm. 2011 Jul;4(3):176. doi: 10.2174/1874471011104030176. Curr Radiopharm. 2011. PMID: 22201706
-
Tumor imaging and therapy using radiolabeled somatostatin analogues.Acc Chem Res. 2009 Jul 21;42(7):873-80. doi: 10.1021/ar800188e. Acc Chem Res. 2009. PMID: 19445476
-
Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.Cancer Biother Radiopharm. 2002 Feb;17(1):107-18. doi: 10.1089/10849780252824127. Cancer Biother Radiopharm. 2002. PMID: 11915167 Review.
-
Targeted radionuclide therapy--an overview.Curr Radiopharm. 2013 Sep;6(3):152-80. doi: 10.2174/18744710113066660023. Curr Radiopharm. 2013. PMID: 24059327 Review.
Cited by
-
The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.Molecules. 2022 May 10;27(10):3062. doi: 10.3390/molecules27103062. Molecules. 2022. PMID: 35630536 Free PMC article. Review.
-
Evaluation of the Effect of Macrocyclic Ring Size on [203Pb]Pb(II) Complex Stability in Pyridyl-Containing Chelators.Inorg Chem. 2022 Jun 27;61(25):9638-9649. doi: 10.1021/acs.inorgchem.2c01114. Epub 2022 Jun 15. Inorg Chem. 2022. PMID: 35704752 Free PMC article.
-
Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.Cancer Biother Radiopharm. 2020 Sep;35(7):475-484. doi: 10.1089/cbr.2019.3340. Epub 2020 Mar 23. Cancer Biother Radiopharm. 2020. PMID: 32202923 Free PMC article.
-
Advancing Targeted Radionuclide Therapy Through the National Cancer Institute's Small Business Innovation Research Pathway.J Nucl Med. 2019 Jan;60(1):41-49. doi: 10.2967/jnumed.118.214684. Epub 2018 Jul 20. J Nucl Med. 2019. PMID: 30030338 Free PMC article.
-
Targeted α-therapy in non-prostate malignancies.Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):47-53. doi: 10.1007/s00259-021-05405-0. Epub 2021 May 16. Eur J Nucl Med Mol Imaging. 2021. PMID: 33993386 Free PMC article. Review.
References
-
- Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946;132:838–847. - PubMed
-
- Crawford LM. New therapy for non-Hodgkin lymphoma. JAMA. 2002;287(13):1640. - PubMed
-
- Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40(2):122–135. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources